Kairos Pharma, LTD. Insider Ownership | KAPA

Insider Holdings by Owner

900.96K Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

4.21%

■0% pp QoQ

Shares Held by Insiders

900.96K

filed for Sep 2026

■0.00% QoQ

Shares Outstanding

21.42Mn

21,423,300 shares

Direct Holdings

900.96K

Indirect: 0

Net Shares Traded (QoQ)

0

no net change in Sep 2026

Insiders Holding Shares

5

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Over the trailing 12 months, KAPA insiders made no open-market trades in the stock.

Business Quant data puts insider holdings in KAPA at 900.96K shares across insiders' latest Form 4 filings, or 4.21% of the 21.42Mn shares outstanding; that total is unchanged from 900.96K shares at the end of Q2 2026.
None of the 900.96K shares held by Kairos Pharma insiders is held through trusts, partnerships or family members; all are direct holdings.
Per Business Quant, 5 insiders of KAPA hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
Kairos Pharma's three largest insider shareholders, based on their latest Form 4 filings, are Ramachandran Murali (VP of Research and Development, 299.53K shares), Doug Samuelson (Chief Financial Officer, 293.04K shares) and John S. Yu (CEO and Chairman, 230.1K shares).
Ramachandran Murali alone accounts for 33.25% of the shares held by Kairos Pharma insiders.
In the last 12 months, 5 Form 4 filings with transactions in KAPA stock came from 5 insiders.
The insider holdings and trades above for Kairos Pharma reflect Form 4 filings through November 26, 2025.

Form 4 Holdings

Insiders Holding KAPA

Insiders 5

Shares held 900.96K

Of outstanding 4.21%

#	Insider	Position	Direct	Total	Share of Insiders	Last Filed
1	Ramachandran Murali	Vp Of Research And Development	299,529	299,529	33.2%	26 Nov, 2025
2	Doug Samuelson	Chief Financial Officer	293,039	293,039	32.5%	26 Nov, 2025
3	John S Yu	Ceo And Chairman	230,105	230,105	25.5%	26 Nov, 2025
4	Rahul Singhvi	Director	49,204	49,204	5.5%	26 Nov, 2025
5	Hansoo Michael Keyoung	Director	29,084	29,084	3.2%	26 Nov, 2025

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

11 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
16 Sep, 2025	Hansoo Michael Keyoung	Director	Acquired A	10,000	$0.00	$0	10,000	Direct
08 Oct, 2025	Ramachandran Murali	Vp Of Research And Development	Acquired A	152,672	$0.00	$0	299,529	Direct
08 Oct, 2025	John S Yu	Ceo And Chairman	Acquired A	190,840	$0.00	$0	230,105	Direct
08 Oct, 2025	Rahul Singhvi	Director	Acquired A	19,084	$0.00	$0	49,204	Direct
08 Oct, 2025	Doug Samuelson	Chief Financial Officer	Acquired A	152,672	$0.00	$0	293,039	Direct
08 Oct, 2025	Hansoo Michael Keyoung	Director	Acquired A	19,084	$0.00	$0	29,084	Direct
01 Jan, 2025	John S Yu	Ceo And Chairman	Acquired A	14,000	$0.00	$0	5,355,838	Direct
01 Jan, 2025	Ramachandran Murali	Vp Of Research And Development	Acquired A	14,000	$0.00	$0	147,057	Direct
22 Nov, 2024	Doug Samuelson	Chief Financial Officer	Acquired P	2,500	$1.50	$3.75K	60,796	Direct
25 Nov, 2024	Ramachandran Murali	Vp Of Research And Development	Acquired P	200	$1.59	$318	133,057	Direct
20 Nov, 2024	John S Yu	Ceo And Chairman	Acquired P	4,000	$1.44	$5.76K	5,341,837	Direct

Kairos Pharma KAPA Insider Ownership